Jazz Pharmaceuticals (JAZZ) Net Cash Flow (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Net Cash Flow of $452.8 million for Q1 2026, up 181.93% year-over-year from $160.6 million in Q1 2025, and up 588.19% quarter-over-quarter from $65.8 million in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Net Cash Flow (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Net Cash Flow history runs 17 years deep, the most recent figure standing at $452.8 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 181.93% year-over-year to $452.8 million; the TTM figure through Mar 2026 stood at -$22.0 million (down 105.28% YoY), while the FY2025 annual figure was -$1.0 billion, down 213.13% from the prior year.
- Net Cash Flow for Q1 2026 stood at $452.8 million, up from $65.8 million in the prior quarter.
- The five-year high for Net Cash Flow was $859.3 million in Q3 2024, with the low at -$676.6 million in Q2 2025.
- The 5-year median for Net Cash Flow is $114.4 million (2023), against an average of $73.7 million.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow surged 1479.44% in 2024, then tumbled 802.71% in 2025.
- Jazz Pharmaceuticals' Net Cash Flow stood at $37.2 million in 2022, then surged by 353.98% to $168.8 million in 2023, then climbed by 16.7% to $197.0 million in 2024, then sank by 66.6% to $65.8 million in 2025, then soared by 588.19% to $452.8 million in 2026.
- Business Quant data shows JAZZ's Net Cash Flow at $452.8 million in Q1 2026, $65.8 million in Q4 2025, and $136.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | -223.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -223.90 Mn |
| Jun 30, 2026 | -223.90 Mn |
| Mar 31, 2026 | 452.80 Mn |
| Mar 31, 2026 | 452.80 Mn |
| Dec 31, 2025 | 65.80 Mn |
| Dec 31, 2025 | 65.80 Mn |
| Sep 30, 2025 | 135.99 Mn |
| Sep 30, 2025 | 135.99 Mn |
| Jun 30, 2025 | -676.60 Mn |
| Jun 30, 2025 | -676.60 Mn |
| Mar 31, 2025 | -552.70 Mn |
| Mar 31, 2025 | -552.70 Mn |
| Dec 31, 2024 | 197.02 Mn |
| Dec 31, 2024 | 197.02 Mn |
| Sep 30, 2024 | 859.26 Mn |
| Sep 30, 2024 | 859.26 Mn |
| Jun 30, 2024 | -86.82 Mn |
| Jun 30, 2024 | -86.82 Mn |
| Mar 31, 2024 | -61.23 Mn |
| Mar 31, 2024 | -61.23 Mn |